Skip to content

XOMA Corporation XOMA Cash & Equivalents

Cash & Equivalents at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$115.09M+140%
Royalty Pharma logo
Royalty PharmaRPRX
$586.4M-46.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$288.1M+160%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$603.09M+89.0%
Zymeworks logo
ZymeworksZYME
$244.28M+221%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$175M+37.8%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's cash & equivalents?
XOMA Corporation (XOMA) reported cash & equivalents of $85.6M in Q1 2026.
How has XOMA Corporation's cash & equivalents changed year-over-year?
XOMA Corporation's cash & equivalents decreased by 5.2% year-over-year, from $90.27M to $85.6M.
What is the long-term trend for XOMA Corporation's cash & equivalents?
Over 5 years (2020 to 2025), XOMA Corporation's cash & equivalents has grown at a -0.3% compound annual growth rate (CAGR), from $84.22M to $82.91M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.